Osteoporosis is a skeletal pathology characterized by compromised bone strength leading
to increased risk of fracture, mainly the spine and hip fractures. Osteoporosis affects more …

The goal of osteoporosis management is to prevent fractures. Several pharmacological
agents are available to lower fracture risk, either by reducing bone resorption or by …

Introduction: Denosumab is a fully human monoclonal antibody against the receptor
activator of nuclear factor kappa-B ligand. It is an antiresorptive agent that reduces …

Denosumab, a fully human monoclonal antibody to RANK ligand [RANK-L]) was approved
for the treatment of postmenopausal osteoporosis in June 2010, and is highly effective in …

Introduction: Osteoporotic fracture is a cause of pain, loss of autonomy and excess mortality.
Current drugs however, do not allow for a satisfactory non vertebral fracture risk reduction …

Introduction: Osteoporosis and fragility fractures are important public health concerns.
Cathepsin K inhibitors, including odanacatib, are a novel class of medications for …

Denosumab is a fully human monoclonal antibody that inhibits the formation, function and
survival of osteoclasts, preventing the interaction of tumor necrosis factor ligand superfamily …

Highlights•Dmab shows unexpected bone formation in contrast to classic antiresorptive
agents.•RANKL pathway and reverse signaling regulate bone formation via …

Osteoclasts, the only cells with bone resorption functions in vivo, maintain the balance of
bone metabolism by cooperating with osteoblasts, which are responsible for bone formation …

Postmenopausal osteoporosis is characterized by bone remodeling alterations with an
imbalance between excessive bone resorption and inadequate bone formation. At present …